Brandon Collins

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

Mark E. Schnute, Patrick O’Brien, Joe Nahra et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 50 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors

Alexander Heim‐Riether, Steven J. Taylor, Shuang Liang et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 50 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Fragment-Based Discovery of Indole Inhibitors of Matrix Metalloproteinase-13

Steven J. Taylor, Asitha Abeywardane, Shuang Liang et al. · Journal of Medicinal Chemistry · 2011 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of<i>N</i>-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2<i>S</i>,5<i>R</i>)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Peter Ruminski, Mark A. Massa, Joseph W. Strohbach et al. · Journal of Medicinal Chemistry · 2015 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability

Donghong A. Gao, Zhaoming Xiong, Alexander Heim‐Riether et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12